Analysts' Actions: A AGN COH NWL WAT

NEW YORK ( TheStreet) -- CHANGE IN RATINGS

Agilent ( A) was downgraded at Goldman Sachs to neutral. $47 price target. Company lacks near-term catalysts, Goldman said.

Allergan ( AGN) was downgraded at Wells Fargo to market perform. Restasis will likely soon face generic competition, Wells Fargo said.

Bunge ( BG) was downgraded to hold at TheStreet Ratings.

Coach ( COH) was downgraded at Lazard Capital Markets to neutral from buy. Company could face increased competition, Lazard Capital Markets said.

Diana Containerships ( DCIX) was downgraded to sell at TheStreet Ratings.

Newell Rubbermaid ( NWL) was initiated with a neutral rating at Goldman Sachs. $27 price target. Valuation call, as the stock is up 70% from its 2011 lows, Goldman said.

Waters ( WAT) was upgraded at Goldman Sachs to buy. $120 price target. Company is seeing better end-market demand, Goldman said.

STOCK COMMENTS/EPS CHANGES

Apple ( AAPL) estimates, price target were cut at Oppenheimer. Shares are now seen reaching $460. Estimates were reduced, given slower iPhone demand, Oppenheimer said. Outperform rating.

Amazon ( AMZN) estimates were reduced at UBS. AMZN 2014 earnings estimates were cut given moderating sales trends in the retail business, said UBS.

Blackberry ( BBRY) numbers were reduced at Citigroup. Earnings estimates were reduced as competition affects demand, said Citi. Price target is $10.

Freeport McMoRan ( FCX) earnings estimates were adjusted at UBS to reflect production losses at Grasberg and a new oil and gas outlook, UBS said.

Inergy ( NRGY) numbers were cut at UBS to reflect the dilution related to the CMLP deal, said UBS. Price target was reduced to $16.

>To submit a news tip, email: tips@thestreet.com.

Follow TheStreet on Twitter and become a fan on Facebook.
This article was written by a staff member of TheStreet.

If you liked this article you might like

What a Difference a Day Makes for New SEC Rule

Jim Cramer: Agilent Technology Has Been One of My Favorites

Jim Cramer -- Agilent Is 'Continuing to Defy Gravity'

Biotech Movers: Disappointment for Bristol-Myers Kidney Combo Boosts Exelixis